Evidence map›Paper›PMID 26312006›Full record

ArticleJournal of pharmacology & pharmacotherapeutics

Complete resistance after maximal dose of rocuronium.

Annalisa Capuano, Maria Giuseppa Sullo, Concetta Rafaniello, Liberata Sportiello, Pierfrancesco Fusco, Macella De Vizia, Fausto Ferraro

Erratum issuedOpen access · hybridAbstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of pharmacology & pharmacotherapeutics. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
2.1field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 8 citations in OpenAlex.

  1. Trial
  2. Erratum: Complete resistance after maximal dose of rocuronium.Journal of pharmacology & pharmacotherapeutics
    Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

Annalisa CapuanoDepartment of Experimental Medicine, Section of Pharmacology, Pharmacoepidemiology and Pharmacovigilance Center of the Campania Region, Second University of Naples, Caserta, Italy.
Maria Giuseppa SulloDepartment of Experimental Medicine, Section of Pharmacology, Pharmacoepidemiology and Pharmacovigilance Center of the Campania Region, Second University of Naples, Caserta, Italy.
Concetta RafanielloDepartment of Experimental Medicine, Section of Pharmacology, Pharmacoepidemiology and Pharmacovigilance Center of the Campania Region, Second University of Naples, Caserta, Italy.
Liberata SportielloDepartment of Experimental Medicine, Section of Pharmacology, Pharmacoepidemiology and Pharmacovigilance Center of the Campania Region, Second University of Naples, Caserta, Italy.
Pierfrancesco FuscoDepartment of Anesthesia and Intensive Care, San Salvatore Hospital, L'Aquila, Italy.
Macella De ViziaDepartment of Anesthetic, Surgical, and Emergency Science - Intensive Care Unit, Second University of Naples, Naples, Caserta, Italy.
Fausto FerraroDepartment of Anesthetic, Surgical, and Emergency Science - Intensive Care Unit, Second University of Naples, Naples, Caserta, Italy.
University of Campania "Luigi Vanvitelli" · ITSan Salvatore Hospital · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Rocuronium is a non-depolarizing neuromuscular blocking agent (NDNMBA), employed in the clinic as an adjunct to general anesthesia to facilitate tracheal intubation rapid sequence, and to provide skeletal muscle relaxation during surgery. Many cases of resistance to neuromuscular blocking agents (NMBAs) have been anecdotally reported. There are specific pathologic states, such as upper motor neuron lesions, severe thermal injuries, liver disease, renal failure, disuse atrophy, all of which show an increased resistance to the effects of nondepolarizing muscle relaxants. Also concurrent drug therapy can alter the efficacy of NMBAs such as some classes of antibiotics, furosemide, β receptor agonists, phosphodiesterase inhibitors, calcium antagonists, respiratory stimulants but also ketamine, propofol and barbiturates at high concentrations. In this scenario we describe an unusual case of 20-years-old man who showed a complete resistance to rocuronium maybe due to a glucocorticoids concomitant therapy.

Indexed as

Drug therapeutic failureglucocorticoidsneuromuscular blockrocuronium

Identifiers

PMID26312006
PMCPMC4544144
OpenAlexW1596769024

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-SA
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.